The purpose of the Re-Spire Study is to help researchers learn more about the efficacy and long-term safety and tolerability of the research drug L606 in participants with PH-ILD.
There are two phases of the Re-Spire Study participants can potentially join with the second phase starting directly after the first phase ends. The first phase is called the "Blinded Treatment Phase" (BTP). This is the "double-blind," assigned by chance portion of the study and will last approximately 28 weeks (a 30-day Screening period followed by a 24-week study period). The second phase of the Re-Spire Study is called the "Open Label Extension Phase" (OLEP). This phase is optional. It is called "open-label" because there is no placebo and everyone who joins will take the active study drug, L606.
About 350 participants will take part in this research study from around 120 study centers or research sites in various countries or regions.

Researchers at the Medical University of South Carolina are studying speech and language in people with Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA), and in healthy adult volunteers. These conditions can change how a person speaks and uses language, and the changes may differ from one condition to another. The study uses a tablet-based set of short speech and language tasks, called SLANG, together with computer software that measures features of the recorded speech, such as pitch, timing, and word choice. Participants also complete standard speech, language, and thinking tests and a brief exam by a neurologist, which researchers compare against the tablet measurements. The purpose of this study is to gather early research data: to build a database of these measurements across the groups, to check whether the tablet captures them reliably, and to explore whether they differ between conditions. SLANG is not used to diagnose participants or to guide their medical care in this study. The long-term goal of this research is to develop a tool that could someday help clinicians recognize and tell these conditions apart earlier, but testing such a tool for diagnosis is beyond the scope of the current study.

This study aims to evaluate the clinical development program for icotrokinra in the treatment of adult participants with moderately to severely active UC. Icotrokinra may offer additional advantages beyond injectable antibody therapies and available
oral therapies for the treatment of patients with moderate to severely active UC due to its oral route of administration, high local exposure to GI tissues, and systemic activity. Overall, the program will evaluate icotrokinra treatment in a target of 822 adult and 60 adolescent participants through at least 52 weeks but participants can participate in a long-term extension for 4 years (total duration approximately 5 years).

This study is recruiting pediatric patients who have been diagnosed with Favorable Histology Wilms Tumor (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. The goal of the study to improve outcomes within cohorts of FHWT patients with current long-term EFS rates at or below 80% and maintain outcomes despite therapy reduction within cohorts of FHWT patients with current long-term EFS rates at or above 84%. Common side effects of treatment in regards to this study include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and orally. Study participation is expected to be approximately 5 years.